Member Info for Jarv55

Adam where is that share holders list from?

Nice Watty reminds me of Pyc this one.

Fairview are you an ex holder? Or working for the mms?

29,571,605 Ordinary Shares in issue (noting any held as treasury shares) and, insofar as it is aware, the percentage of AIM securities that is not in public hands is 33.3%.

Herald Investment Management Limited 4,031,490 13.63
Amati Global Investors Limited 3,164,557 10.70
Alto Invest 2,985,410 10.10
Cancaccord Genuity Wealth Mgmt 1,884,076 6.37
Antrak Limited 1,852,210 6.26
Gresham House 1,582,279 5.35
Bury Fitzwilliam-Lay and Partners LLP 1,459,460 4.94
Chelverton Asset Management Limited 1,225,000 4.14
The Capital for Enterprise Fund LP 889,080 3.01
Canaccord Genuity Wealth Mgmt 886,076 3.00
Director Holdings
Simon Crowther 868,475 2.94
Alyson Levett 777,796 2.63
Richard Cunningham* 1,083,100 3.66
Nigel Halkes 20,331 0.07

*this includes 7,740 shares held by Richard Cunningham’s wife

Have a listen to this ANTIBODY TEST interview https://quotientbd.com/news/quotient-ceo-franz-walt-talkradio-mike-graham

Sorry wrong bb admin please take it down

https://quotientbd.com/news/quotient-ceo-franz-walt-talkradio-mike-graham
listen to this

Orph have 4 million in the bank how much revenues does the antibody add?

So products go into Imutex

Interesting Imutex they will let Nasdaq decide the value that won't be held back.

Listen very carefully he believes you will only get high accuracy antibody tests using a blood draw method. If they get this antibody test up and running in two weeks it will be in the press and they are doing everything including selling it. I would expect a government contract. This is buy one Orph share get another 1 share in a new company listing on Nasdaq. Listen very carefully 13.25 mins in 14.40mins 26mins make notes.

This is a gem listen to the video very carefully 13.20 mins in and 14.40 mins in
they are working with Roche.

Interesting post in the telegram group
From Stockopedia "BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect"
This company is on Nasdaq and is valued at $200million we have far more in the pipeline.

Personally think it prevents us being given a speeding ticket by the nomad he has covered himself in the interview.

Cathal Friel, Executive Chairman of Open Orphan, said:

"We are delighted to exclusively partner with Quotient Limited to bring fast and accurate COVID-19 antibody testing to the UK. Open Orphan plc, via our subsidiary hVIVO, has industry leading scientific and laboratory capability and the MosaiQ™ system's best in class COVID-19 antibody testing performance makes the system a natural addition to our state-of-the-art virology laboratory in London. There is a clear demand for COVID-19 antibody testing and we will be making testing available both as a standalone offering and will also utilize the testing capability to screen volunteers for our industry leading range of human challenge studies to ensure no disruption to our clients."

Franz Walt, Chief Executive Officer of Quotient, said:

"This collaboration marks a major milestone for our company, and we are proud to collaborate with an industry leader like hVIVO. Quotient has developed what we believe is a gold standard antibody microarray to help combat the COVID-19 pandemic. This collaboration is uniquely positioned to leverage our combined expertise, and helps address the large need for antibody testing in the U.K. and beyond." said Franz Walt, Chief Executive Officer of Quotient.

Major New Contract with US Biotechnology Company

The company has signed a contract with a US Biotech company for the provision of an RSV human challenge study with work to deliver the study expected to commence shortly. The contract is projected to deliver £3.5 million in revenue all of which is expected to be recognised in 2020. The signing of this new contract follows the signing in March of this year of another RSV human challenge contract, now underway, for an initial £3.2 million.

This contract represents continued conversion of Open Orphan's substantial pipeline, generation of significant cash flow and further validates its position as world leader in the provision of viral challenge studies, vaccine and viral laboratory services, supporting product development for customers developing antivirals, vaccines and respiratory therapeutics. These services are particularly relevant and topical in environment of heightened awareness of virology following the onset of Covid-19.

This study will commence in hVIVO's unique London-based quarantine unit in the third quarter of 2020, which is Europe's only commercial 24-bed quarantine clinic with on-site virology laboratory. hVIVO is the only company globally with the capability to run an RSV human challenge study.

This agreement utilises what is now a broader and complementary in-house service offering. All aspects of the study will be conducted within Open Orphan, with data management, biostats and medical writing being provided by our Venn Life Sciences colleagues leading to the elimination of sub-contractor costs and retention of more contracted revenue. We look forward to delivering the work for this US Biotech Company and further developing our relationship.

Fairview you might want to watch this aswell that is funniest thing I have read in a very long time
https://www.youtube.com/watch?v=3TEVZwR5FLs&feature=youtu.be

https://www.thetimes.co.uk/article/coronavirus-vaccine-race-volunteers-to-be-infected-in-the-uk-ck0s72x8k

Fairview lol do some research
Wall Street JournalMon 22:13

Another piece today in the Wall Street Journal weighing up Challenger studies for vaccines.

Small quote from Cathal embedded in the article:

"A company in London called hVIVO that specializes in human challenge trials is “very actively looking into how we could build a Covid-19 challenge study to help speed up the world wide development of an effective vaccine,” said Cathal Friel, executive chairman of Open Orphan, a clinical trials company that acquired hVIVO earlier this year. He says at least 10 pharmaceutical companies have already expressed interest in them potentially conducting a challenge trial of their vaccine candidates."

https://fortunascorner.com/2020/05/11/one-idea-for-speeding-a-coronavirus-vaccine-deliberately-infecting-people/